187 related articles for article (PubMed ID: 12436438)
41. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.
Atzpodien J; Körfer A; Franks CR; Poliwoda H; Kirchner H
Lancet; 1990 Jun; 335(8704):1509-12. PubMed ID: 1972442
[TBL] [Abstract][Full Text] [Related]
42. [Prognostic predictive factors of the clinical response to immunotherapy with subcutaneous interleukin-2, in patients with metastatic renal carcinoma: analysis of 60 cases].
Lissoni P; Scardino E; Favini P; Barni S; Tancini G; Baccalin A; Verweij F; Strada G; Musci R; Rocco F
Arch Ital Urol Androl; 1995 Apr; 67(2):149-53. PubMed ID: 7787857
[TBL] [Abstract][Full Text] [Related]
43. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.
Lissoni P; Barni S; Archili C; Cattaneo G; Rovelli F; Conti A; Maestroni GJ; Tancini G
Anticancer Res; 1990; 10(3):753-7. PubMed ID: 2142395
[TBL] [Abstract][Full Text] [Related]
44. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung.
Ziegler LD; Palazzolo P; Cunningham J; Janus M; Itoh K; Hayakawa K; Hellstrom I; Hellstrom KE; Nicaise C; Dennin R
J Clin Oncol; 1992 Sep; 10(9):1470-8. PubMed ID: 1517790
[TBL] [Abstract][Full Text] [Related]
45. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
Pavone L; Andrulli S; Santi R; Majori M; Buzio C
Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of cancer of the kidney with interleukin 2 in adults, the Lyon experience].
Negrier S; Mercatello A; Coronel B; Ravaud A; Merrouche Y; Bret M; Lanier F; Moskovtchenko JF; Philip T
J Chir (Paris); 1992; 129(6-7):292-6. PubMed ID: 1474110
[TBL] [Abstract][Full Text] [Related]
47. Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.
Sznol M; Steis RG; Smith JW; Janik JE; Sharfman WH; Urba WJ; Fenton RG; Creekmore SP; Beveridge J; Longo DL
Online J Curr Clin Trials; 1992 Jul; Doc No 9():[3841 words; 32 paragraphs]. PubMed ID: 1343617
[TBL] [Abstract][Full Text] [Related]
48. Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.
Négrier S; Mercatello A; Bret M; Thiesse P; Blay JY; Coronel B; Merrouche Y; Oskam R; Franks CR; Clavel M
Br J Cancer; 1992 May; 65(5):723-6. PubMed ID: 1586600
[TBL] [Abstract][Full Text] [Related]
49. Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy.
Paolorossi F; Villa S; Barni S; Tancini G; Andres M; Lissoni P
Tumori; 1995; 81(1):45-7. PubMed ID: 7754541
[TBL] [Abstract][Full Text] [Related]
50. Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study.
Fosså SD; Gunderson R; Moe B
Cancer; 1990 Jun; 65(11):2451-4. PubMed ID: 2337859
[TBL] [Abstract][Full Text] [Related]
51. Sequential subcutaneous thymopentin, interferon alpha-2a and interleukin-2 in metastatic renal cell cancer.
Di Lauro L; Del Medico P; Carpano S; Cancrini A; Gionfra T; Vici P; Rosselli M; Lopez M
Tumori; 1995; 81(1):42-4. PubMed ID: 7754540
[TBL] [Abstract][Full Text] [Related]
52. A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study.
Murphy BR; Rynard SM; Einhorn LH; Loehrer PJ
Invest New Drugs; 1992 Aug; 10(3):225-30. PubMed ID: 1428732
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum.
Figlin RA; Callaghan M; Sarna G
Cancer Treat Rep; 1983 May; 67(5):493-4. PubMed ID: 6850664
[TBL] [Abstract][Full Text] [Related]
54. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Passalacqua R; Buzio C; Buti S; Porta C; Labianca R; Pezzuolo D; Camisa R; Sabbatini R; Benecchi L; Messina C; Cengarle R; Vaglio A; Dalla Chiesa M; Tomasello G; Caminiti C
Cancer Immunol Immunother; 2010 Apr; 59(4):553-61. PubMed ID: 19779715
[TBL] [Abstract][Full Text] [Related]
55. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Linehan WM; Seipp C; Calabro S; Karp SE; Sherry RM; Steinberg S; White DE
J Clin Oncol; 1989 Dec; 7(12):1863-74. PubMed ID: 2685181
[TBL] [Abstract][Full Text] [Related]
56. [Treatment of advanced renal cell carcinoma with a combination of interferon alpha and gamma].
Naito S; Yasumasu T; Kumazawa J; Hiratsuka Y; Sakamoto K; Iguchi A; Masaki Z; Hasui Y; Osada Y; Kurozumi T
Nihon Hinyokika Gakkai Zasshi; 1995 Aug; 86(8):1346-52. PubMed ID: 7474618
[TBL] [Abstract][Full Text] [Related]
57. Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
Stadler WM; Vogelzang NJ; Vokes EE; Charette J; Whitman G
Cancer Chemother Pharmacol; 1992; 31(3):213-6. PubMed ID: 1464158
[TBL] [Abstract][Full Text] [Related]
58. Treatment of renal cell carcinoma with daily low-dose alpha-interferon.
Marshall ME; Simpson W; Butler K; Fried A; Fer M
J Biol Response Mod; 1989 Oct; 8(5):453-61. PubMed ID: 2795090
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer.
Jansen RL; Slingerland R; Goey SH; Franks CR; Bolhuis RL; Stoter G
J Immunother (1991); 1992 Jul; 12(1):70-3. PubMed ID: 1322167
[TBL] [Abstract][Full Text] [Related]
60. Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma.
Huland E; Huland H; Heinzer H
J Urol; 1992 Feb; 147(2):344-8. PubMed ID: 1732590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
